The 21-valent pneumococcal conjugate vaccine candidate, GBP410 (also known as SP0202), demonstrates positive safety and immunogenicit...
Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) biosimilar offers US patients reduced injection volume in citrate-free formulation A...
Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon...
Thermo Fisher Scientific, a global leading company in science services, today announced the launch of the Gibco™ OncoPro™ tumor media kit. *, t...
In VIRAGE, the ongoing multinational Phase 2b clinical study, intravenous VCN-01 is being evaluated in combination with standard-of-care (SoC) chemotherapy...
-Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
CAMZYOS is the first and only cardiac myosin inhibitor approved in the European Union Approval based on two positive Phase 3 trials, EXPLORER-HCM and VALO...
U.S. Food and Drug Administration published a new draft guidance to highlight fundamental considerations to researchers investigating the use of psychedeli...
Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 45690...
The STARBURST study (ClinicalTrials.gov Identifier: NCT05563272) is a prospective, open label Phase II "basket" study to investigate CAIX expression in pat...
Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response (remission) rate and a median duration of response of 1...
CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, announced that its CE...
– Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface’s anticipated net cash of $20 to $25 ...
This three-year collaboration aims to validate genetic drug targets and progress therapeutic molecules into clinical development. The joint resea...
© 2025 Biopharma Boardroom. All Rights Reserved.
